Access to personalized cancer treatments is now becoming a reality in Greece! The recent decision by the Ministry of Health (Government Gazette B’ 5627/20-10-2025, Decision Δ3(α) 41081/2025) approving and reimbursing important biomarkers marks a crucial step toward modern oncology care.
Biomarkers are essentially specific indicators detected through molecular tests, helping doctors select the most suitable treatment for each patient based on the characteristics of their tumor. Until recently, only certain key biomarkers had been included in Greece’s public electronic prescription system, such as molecular signatures guiding chemotherapy decisions in early breast cancer (2018) and tests for hereditary breast and ovarian cancer through BRCA1/2 gene mutations.
The new decision significantly expands the approval and reimbursement of biomarkers, covering additional biomarkers for 39 indications. This allows oncologists to tailor treatment based on the precise characteristics of each patient’s tumor.
With this initiative, Greece moves closer to adopting international practices in personalized medicine and aligns with key principles of the European Cancer Strategy, reducing inequalities and enhancing access to innovative therapies.
Updating and expanding biomarkers in the public prescription system will continue to meet the growing needs of clinical practice. This is a dynamic step that, while just the beginning, lays solid foundations for continuous progress and improvement in patients’ quality of life.
This progress is not just about technology or medications—it is fundamentally about people. Every new approval, every update to the biomarker list, represents a step toward holistic patient care, strengthening trust and hope that Greece can provide modern, safe, and effective solutions in oncology treatment.
Through these steps, patients and their families can feel that the country is investing not only in innovation but also in meaningful support. The journey of personalized oncology care in Greece has just begun—and the outlook is promising.
Read the Government Gazette here
Learn more about cancer biomarkers here
Text/Adaptation: Ifiyenia Anastasiou for Kapa3
